GIMBHI’s daily mental health update — 06/23/26

🏥 Klinic raises $24M Series A for specialty provider-enablement platform (HLTH) — 06/10/26
TL;DR: Texas-based Klinic, the “Shopify for healthcare,” raised $24M Series A to expand its provider-enablement platform—now spanning behavioral health, oncology, cardiology, and rare diseases—for independent specialty practices.

🩸 Ketim Technologies awarded $250K for postpartum depression biomarker diagnostic (Clarissa Yates, LinkedIn) — 06/2026
TL;DR: Ketim Technologies won $250K from Australia’s Industry Growth Program Early Commercialisation Fund to develop a prototype CE-IVD diagnostic device using biomarkers for postpartum depression.

🏛️ How state Medicaid uncertainties are reshaping the SUD treatment environment (Ashleigh Hollowell, Behavioral Health Business) — 06/23/26
TL;DR: As OBBBA provisions near, addiction treatment providers face state-level Medicaid volatility—uneven reimbursement rates and coverage losses from paperwork burdens—pushing them to hire navigators, diversify payers, and prove value.

💊 Neumora to lay off 35% of staff after navacaprant goes 0 for 3 in late-stage depression studies (Eric Sagonowsky, Fierce Biotech) — 06/15/26
TL;DR: Neumora is discontinuing navacaprant and cutting 35% of staff after its Koastal-2 and Koastal-3 trials failed to beat placebo in major depression, completing three straight Phase 3 misses and sinking its stock ~95% from its 2025 peak.